Poster: Cost Impact Analysis of Lepzi® POC PlGF Testing in Suspected Pre-eclampsia
A new cost impact analysis evaluating the Lepzi® point-of-care (POC) Placental Growth Factor (PlGF) test in women with suspected pre-eclampsia was presented in March at the British Maternal and Fetal Medicine Society Annual Conference 2026.
The poster, titled “Cost Impact Analysis of Using Lepzi Point of Care (POC) Placental Growth Factor (PlGF) Test in Women with Suspected Preeclampsia”, was authored by Professor Rachael M. Hunter (University College London) and Dr Jayne E. Ellis (JEMMDx).
View full poster here.
Using data from the PARROT randomised controlled trial and a decision-analytic model, the analysis explored the financial impact of incorporating Lepzi POC PlGF testing into the management pathway for women presenting with suspected pre-eclampsia before 37 weeks’ gestation. The findings demonstrate significant potential cost savings compared with standard care (no PlGF testing), as well as additional savings when switching from laboratory-based PlGF tests to Lepzi.
The authors conclude that near-patient PlGF testing with Lepzi may support faster risk stratification, reduce unnecessary resource use, and improve care efficiency—particularly in settings where rapid laboratory access is limited.
View full poster here.
